Amerise Biosciences: Profitable Year Masks Q4 Slide and Dormant Operations

Annual Results Show Profit Growth, Q4 Slump

Amerise Biosciences Ltd. has released its audited financial results for the fiscal year ending March 31, 2026. The company reported a net profit of ₹1.61 Lakhs on total income of ₹25.52 Lakhs for the full year. This represents a significant 182.46% increase in net profit and a 35.74% rise in total income compared to the previous fiscal year.

However, the fourth quarter (Q4 FY26) presented a stark contrast. Standalone total income for the quarter fell to ₹7.92 Lakhs, a substantial decrease of 57.87% from ₹18.80 Lakhs in the same quarter last year. Net profit for Q4 FY26 was ₹6.13 Lakhs.

The company's auditors issued an "Unmodified Opinion" on the FY26 financial statements, confirming a clean audit report. Amerise Biosciences maintained profitability throughout the year, supported by its equity base of ₹539.59 Lakhs.

Dormant Business Masks Profit Source

Amerise Biosciences operates with minimal business activity. Its financial outcomes are heavily influenced by 'Other Income' sources rather than core operations. This year's profit and revenue growth are largely a reflection of these non-operational income streams, not a revival of active business.

The sharp drop in Q4 revenue, alongside current financial liabilities of ₹202.00 Lakhs, highlights ongoing operational challenges and financial constraints for the micro-cap entity.

History of Dormancy and Non-Operational Income

Incorporated in 1984, Amerise Biosciences was formerly known as Amradeep Industries Limited. The company was previously engaged in commodity trading, including castor seeds. However, due to past financial difficulties, it has been operationally dormant for several years.

Activities such as commodity and castor seed trading have ceased, with zero revenue reported from operations in FY2023-24 and FY2024-25. Consequently, the company's financial results are primarily driven by interest earnings, capital gains, and other non-operational income.

Audited Figures Confirm Reliance on Other Income

These audited results provide shareholders with a clear view of the company's financial position for FY26. They confirm the extent of reliance on 'Other Income' and the auditor's positive assessment of the company's financial health. The figures highlight the micro-cap nature of the company and its limited operational footprint.

Key Risks for Investors

• Dormant Operations: The company's core business activities remain negligible, making its financial stability dependent on non-operational income, which can be volatile.
• Q4 Performance: The significant year-on-year decline in Q4 revenue is a red flag for the company's immediate operational performance.
• Small Scale: With annual revenues in the range of ₹25.52 Lakhs, the company is extremely small, leading to high volatility in its financial metrics and stock price.
• Liabilities: Current financial liabilities amounting to ₹202.00 Lakhs present a short-term financial pressure point.

Limited Peer Comparison Due to Scale and Operations

Amerise Biosciences operates in a sector often categorized with pharmaceuticals, though its current business is dormant and historical focus was commodity trading. Major Indian pharmaceutical players like Dr. Reddy's Laboratories, Cipla, and Sun Pharma are significant entities with robust operations, R&D, and global reach.

In contrast, Amerise Biosciences's scale and lack of active business operations make direct peer comparison challenging. Its closest comparables might be other micro-cap entities with similar operational dormancy or unique 'other income' models.

Financial Snapshot

Current financial liabilities stood at ₹202.00 Lakhs as of March 31, 2026.

Shareholder equity was ₹539.59 Lakhs as of March 31, 2026.

Looking Ahead

Investors will be watching future quarterly results to judge the sustainability of 'Other Income' as a profit driver.

Any communication regarding potential revival of business operations, however unlikely, will be noteworthy.

The company's ability to manage its current financial liabilities effectively is also key.

Stock price volatility is expected, given the company's low operational base and reliance on non-core income streams.